Crusader Saturday, 05/09/20 04:07:58 PM Re: None Post # of 7994 Before the well is poisoned more by resident bears, consider this Seeking Alpha article about biotech companies capitalizing their developments. The story is NOT finished here even if short bears will not go away and stop saving us from ourselves. Expected capital raises continue to ramp in healthcare amid pandemic May 09, 2020 12:40 PM ETCheck-Cap Ltd. (CHEK)2 Comments The need for capital continues apace for healthcare companies as they deal with COVID-19 disruptions. Stock offerings: Check-Cap (NASDAQ:CHEK): direct placement of 5M ordinary shares at $0.60 per share plus 5 1/2-year warrants to purchase up to 5M shares at $0.80. Friday's close was $0.54. Cellectar Biosciences (NASDAQ:CLRB): $17.5M public offering of stock and five-year warrants. Mixed shelf filings: BioTelemetry (NASDAQ:BEAT): unspecified. Clearside Biomedical (NASDAQ:CLSD): $250M. Arcturus Therapeutics (NASDAQ:ARCT): $200M. Mersana Therapeutics (NASDAQ:MRSN): $250M. CLRB’s DILUTION IS HUNDREDS OF TIMES SMALLER THAN THOSE OTHERS LISTED. The real issue is a cure; no the cost of getting there!